50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,708.29 (+1.67%)
DOW   29,631.17 (+1.70%)
QQQ   277.68 (+1.17%)
AAPL   147.55 (-2.77%)
MSFT   239.76 (+1.42%)
META   139.63 (+3.89%)
GOOGL   99.29 (+1.84%)
AMZN   116.95 (+2.22%)
TSLA   282.82 (-0.04%)
NVDA   125.20 (+0.86%)
NIO   17.16 (-0.17%)
BABA   80.36 (+3.20%)
AMD   67.99 (+1.22%)
T   15.83 (+0.64%)
MU   50.25 (-0.65%)
CGC   2.94 (+2.80%)
F   12.03 (+1.01%)
GE   64.25 (-0.34%)
DIS   98.79 (+3.07%)
AMC   7.53 (+1.07%)
PYPL   89.02 (+3.81%)
PFE   44.60 (+1.16%)
NFLX   241.17 (+7.49%)
S&P 500   3,708.29 (+1.67%)
DOW   29,631.17 (+1.70%)
QQQ   277.68 (+1.17%)
AAPL   147.55 (-2.77%)
MSFT   239.76 (+1.42%)
META   139.63 (+3.89%)
GOOGL   99.29 (+1.84%)
AMZN   116.95 (+2.22%)
TSLA   282.82 (-0.04%)
NVDA   125.20 (+0.86%)
NIO   17.16 (-0.17%)
BABA   80.36 (+3.20%)
AMD   67.99 (+1.22%)
T   15.83 (+0.64%)
MU   50.25 (-0.65%)
CGC   2.94 (+2.80%)
F   12.03 (+1.01%)
GE   64.25 (-0.34%)
DIS   98.79 (+3.07%)
AMC   7.53 (+1.07%)
PYPL   89.02 (+3.81%)
PFE   44.60 (+1.16%)
NFLX   241.17 (+7.49%)
S&P 500   3,708.29 (+1.67%)
DOW   29,631.17 (+1.70%)
QQQ   277.68 (+1.17%)
AAPL   147.55 (-2.77%)
MSFT   239.76 (+1.42%)
META   139.63 (+3.89%)
GOOGL   99.29 (+1.84%)
AMZN   116.95 (+2.22%)
TSLA   282.82 (-0.04%)
NVDA   125.20 (+0.86%)
NIO   17.16 (-0.17%)
BABA   80.36 (+3.20%)
AMD   67.99 (+1.22%)
T   15.83 (+0.64%)
MU   50.25 (-0.65%)
CGC   2.94 (+2.80%)
F   12.03 (+1.01%)
GE   64.25 (-0.34%)
DIS   98.79 (+3.07%)
AMC   7.53 (+1.07%)
PYPL   89.02 (+3.81%)
PFE   44.60 (+1.16%)
NFLX   241.17 (+7.49%)
S&P 500   3,708.29 (+1.67%)
DOW   29,631.17 (+1.70%)
QQQ   277.68 (+1.17%)
AAPL   147.55 (-2.77%)
MSFT   239.76 (+1.42%)
META   139.63 (+3.89%)
GOOGL   99.29 (+1.84%)
AMZN   116.95 (+2.22%)
TSLA   282.82 (-0.04%)
NVDA   125.20 (+0.86%)
NIO   17.16 (-0.17%)
BABA   80.36 (+3.20%)
AMD   67.99 (+1.22%)
T   15.83 (+0.64%)
MU   50.25 (-0.65%)
CGC   2.94 (+2.80%)
F   12.03 (+1.01%)
GE   64.25 (-0.34%)
DIS   98.79 (+3.07%)
AMC   7.53 (+1.07%)
PYPL   89.02 (+3.81%)
PFE   44.60 (+1.16%)
NFLX   241.17 (+7.49%)
NASDAQ:QTNT

Quotient - QTNT Stock Forecast, Price & News

$0.16
+0.01 (+8.97%)
(As of 09/28/2022 12:39 PM ET)
Add
Compare
Today's Range
$0.15
$0.16
50-Day Range
$0.15
$0.28
52-Week Range
$0.14
$3.19
Volume
14,041 shs
Average Volume
3.62 million shs
Market Capitalization
$16.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.25

Quotient MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
1,324.1% Upside
$2.25 Price Target
Short Interest
Healthy
3.14% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.83
Upright™ Environmental Score
News Sentiment
0.66mentions of Quotient in the last 14 days
Based on 7 Articles This Week
Insider Trading
Acquiring Shares
$195,354 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.69) to ($0.32) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.68 out of 5 stars

Medical Sector

177th out of 1,071 stocks

Diagnostic Substances Industry

2nd out of 17 stocks

QTNT stock logo

About Quotient (NASDAQ:QTNT) Stock

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company also offers MosaiQ SDS Microarray that is designed as a serological disease screening microarray comprised assays to detect cytomegalovirus and Syphilis; MosaiQ MDS Microarray that is designed as a molecular disease screening microarray test for donor red cells or source plasma; MosaiQ IH Microarray as a blood grouping microarray; MosaiQ Autoimmune Microarray; MosaiQ COVID-19; and MosaiQ IH3 Microarray. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.

Receive QTNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Quotient and its competitors with MarketBeat's FREE daily newsletter.

QTNT Stock News Headlines

Quotient (NASDAQ:QTNT) Now Covered by StockNews.com
Quotient (NASDAQ:QTNT) Research Coverage Started at StockNews.com
See More Headlines
Receive QTNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Quotient and its competitors with MarketBeat's FREE daily newsletter.

QTNT Company Calendar

Last Earnings
8/09/2022
Today
9/28/2022
Next Earnings (Estimated)
11/21/2022
Fiscal Year End
3/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:QTNT
Fax
N/A
Employees
426
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$2.25
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+1,324.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-125,130,000.00
Net Margins
-357.50%
Pretax Margin
-356.39%

Debt

Sales & Book Value

Annual Sales
$38.51 million
Book Value
($1.40) per share

Miscellaneous

Free Float
92,378,000
Market Cap
$16.31 million
Optionable
Optionable
Beta
2.76

Key Executives

  • Mr. Manuel O. Mendez (Age 54)
    CEO & Director
    Comp: $10.22M
  • Mr. Ali Kiboro (Age 47)
    Chief Financial Officer
    Comp: $798.9k
  • Mr. Mohammad El Khoury (Age 62)
    Chief Commercial Officer
    Comp: $544.83k
  • Ms. Vittoria Bonasso (Age 46)
    Head of Fin., Group Controller & Principal Accounting Officer
  • Dr. Michael Hausmann
    Chief Technology Officer
  • Dr. Christine Ginocchio
    Chief Scientific & Medical Officer
  • Ms. Viviane Montarnal
    Head of Legal Affairs & Compliance
  • Ms. Hyatt Antognini
    Head of Corp. Communications
  • Mr. Christian Albrich (Age 58)
    Chief People Officer
  • Mr. Esteban Uriarte
    Chief Manufacturing Operations Officer













QTNT Stock - Frequently Asked Questions

Should I buy or sell Quotient stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Quotient in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" QTNT shares.
View QTNT analyst ratings
or view top-rated stocks.

What is Quotient's stock price forecast for 2022?

4 analysts have issued twelve-month price objectives for Quotient's stock. Their QTNT share price forecasts range from $1.50 to $3.00. On average, they expect the company's stock price to reach $2.25 in the next year. This suggests a possible upside of 1,430.6% from the stock's current price.
View analysts price targets for QTNT
or view top-rated stocks among Wall Street analysts.

How have QTNT shares performed in 2022?

Quotient's stock was trading at $2.59 on January 1st, 2022. Since then, QTNT shares have decreased by 94.3% and is now trading at $0.1470.
View the best growth stocks for 2022 here
.

When is Quotient's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our QTNT earnings forecast
.

How were Quotient's earnings last quarter?

Quotient Limited (NASDAQ:QTNT) released its quarterly earnings results on Tuesday, August, 9th. The company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by $0.09. The firm earned $8.81 million during the quarter, compared to analysts' expectations of $9.40 million.

What guidance has Quotient issued on next quarter's earnings?

Quotient issued an update on its FY 2023 earnings guidance on Tuesday, September, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $39.00 million-$42.00 million, compared to the consensus revenue estimate of $40.87 million.

What other stocks do shareholders of Quotient own?
What is Quotient's stock symbol?

Quotient trades on the NASDAQ under the ticker symbol "QTNT."

Who are Quotient's major shareholders?

Quotient's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Pura Vida Investments LLC (6.45%), JPMorgan Chase & Co. (3.38%), Walleye Capital LLC (2.91%), Walleye Capital LLC (2.91%), Millennium Management LLC (1.39%) and State Street Corp (0.48%). Insiders that own company stock include Edward Farrell, Frederick Hallsworth, Jeremy Stackawitz, Khoury Mohammad El, Manuel O Mendez, Perceptive Advisors Llc, Peter Buhler, Prondzynski Heino Von and Zubeen Shroff.
View institutional ownership trends
.

How do I buy shares of Quotient?

Shares of QTNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Quotient's stock price today?

One share of QTNT stock can currently be purchased for approximately $0.15.

How much money does Quotient make?

Quotient (NASDAQ:QTNT) has a market capitalization of $15.17 million and generates $38.51 million in revenue each year. The company earns $-125,130,000.00 in net income (profit) each year or ($1.34) on an earnings per share basis.

How many employees does Quotient have?

The company employs 426 workers across the globe.

How can I contact Quotient?

Quotient's mailing address is B1 Business Park Terre Bonne Route de Crassier 13, Eysins Y9, 1262. The official website for the company is www.quotientbd.com. The company can be reached via phone at (122) 716-9800 or via email at ir@quotientbd.com.

This page (NASDAQ:QTNT) was last updated on 9/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.